Cue Operating Income from 2010 to 2024

CUE Stock

USD 1.01 0.01 0.98%

Cue Biopharma's Operating Income is decreasing over the years with slightly volatile fluctuation. Operating Income is expected to dwindle to about -54.8 M. Operating Income is earnings before interest and taxes (EBIT), representing the amount of profit Cue Biopharma generates from its operations. View All Fundamentals

Operating Income

First Reported

2015-12-31

Previous Quarter

-10.4 M

Current Value

-8.8 M

Quarterly Volatility

3.7 M

Yuan Drop

Covid

Check Cue Biopharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Cue Biopharma's main balance sheet or income statement drivers, such as Depreciation And Amortization of 3.6 M, Interest Expense of 1.2 M or Selling General Administrative of 11.7 M, as well as many indicators such as Price To Sales Ratio of 20.9, Dividend Yield of 0.0 or PTB Ratio of 3.09. Cue financial statements analysis is a perfect complement when working with Cue Biopharma Valuation or Volatility modules.

Check out the analysis of Cue Biopharma Correlation against competitors.

For information on how to trade Cue Stock refer to our How to Trade Cue Stock guide.

Latest Cue Biopharma's Operating Income Growth Pattern

Below is the plot of the Operating Income of Cue Biopharma over the last few years. Operating Income is the amount of profit realized from Cue Biopharma operations after accounting for operating expenses such as cost of goods sold (COGS), wages and depreciation. Operating income takes the gross income and subtracts other operating expenses and then removes depreciation. Operating Income of Cue Biopharma is typically a synonym for earnings before interest and taxes (EBIT) and is also commonly referred to as operating profit or recurring profit. It is earnings before interest and taxes (EBIT), representing the amount of profit a company generates from its operations. Cue Biopharma's Operating Income historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Cue Biopharma's overall financial position and show how it may be relating to other accounts over time.

Operating Income

10 Years Trend

Slightly volatile

Compare to Others All Fundamentals

Operating Income

Timeline

Cue Operating Income Regression Statistics

	Arithmetic Mean	(24,454,344)
	Coefficient Of Variation	(91.37)
	Mean Deviation	20,422,689
	Median	(23,233,870)
	Standard Deviation	22,345,016
	Sample Variance	499.3T
	Range	52.8M
	R-Value	(0.95)
	Mean Square Error	55.5T
	R-Squared	0.90
	Slope	(4,731,392)
	Total Sum of Squares	6990.2T

Cue Operating Income History

	2024	-54.8 M
	2023	-52.1 M
	2022	-53.2 M
	2021	-43.7 M
	2020	-45 M
	2019	-36.8 M
	2018	-38.7 M

Other Fundumenentals of Cue Biopharma

Non Operating Income Net Other

Cue Biopharma Operating Income component correlations

	Total Assets	Total Stockholder Equity	Net Tangible Assets	Net Debt	Retained Earnings	Accounts Payable	Short Term Investments	Total Liab	Deferred Long Term Liab	Total Current Assets	Common Stock	Property Plant Equipment	Current Deferred Revenue	Net Receivables	Net Invested Capital	Short Long Term Debt	Net Working Capital	Short Term Debt	Intangible Assets	Capital Surpluse	Capital Stock	Long Term Debt	Long Term Debt Total
Total Assets		0.99	0.97	-0.91	-0.78	0.83	0.54	0.91	0.82	1.0	0.88	0.53	0.69	0.33	0.15	-0.2	-0.09	0.81	-0.84	0.74	0.69	-0.23	-0.23
Total Stockholder Equity	0.99		0.94	-0.95	-0.7	0.76	0.49	0.83	0.82	0.99	0.8	0.52	0.66	0.33	0.2	-0.27	-0.01	0.76	-0.77	0.64	0.59	-0.15	-0.18
Net Tangible Assets	0.97	0.94		-0.91	-0.82	0.89	0.41	0.92	0.84	0.97	0.92	0.48	0.65	0.39	0.04	0.02	-0.2	0.81	-0.82	0.8	0.76	-0.4	-0.31
Net Debt	-0.91	-0.95	-0.91		0.57	-0.68	-0.25	-0.7	-0.79	-0.93	-0.69	-0.44	-0.61	-0.45	-0.2	0.17	-0.02	-0.74	0.62	-0.53	-0.46	0.15	0.15
Retained Earnings	-0.78	-0.7	-0.82	0.57		-0.9	-0.32	-0.91	-0.59	-0.75	-0.94	-0.33	-0.51	-0.4	0.01	-0.3	0.41	-0.81	0.86	-0.95	-0.96	0.71	0.66
Accounts Payable	0.83	0.76	0.89	-0.68	-0.9		0.41	0.92	0.79	0.81	0.96	0.27	0.46	0.42	-0.18	0.17	-0.42	0.8	-0.85	0.89	0.86	-0.54	-0.4
Short Term Investments	0.54	0.49	0.41	-0.25	-0.32	0.41		0.58	0.52	0.53	0.47	0.49	0.49	-0.41	-0.1	-0.55	-0.05	0.21	-0.6	0.29	0.3	0.22	0.21
Total Liab	0.91	0.83	0.92	-0.7	-0.91	0.92	0.58		0.73	0.88	0.98	0.5	0.67	0.3	-0.03	0.01	-0.29	0.82	-0.93	0.91	0.88	-0.45	-0.34
Deferred Long Term Liab	0.82	0.82	0.84	-0.79	-0.59	0.79	0.52	0.73		0.84	0.75	0.53	0.47	0.21	-0.34	-0.1	-0.43	0.55	-0.73	0.5	0.47	-0.24	-0.17
Total Current Assets	1.0	0.99	0.97	-0.93	-0.75	0.81	0.53	0.88	0.84		0.85	0.53	0.69	0.3	0.15	-0.21	-0.07	0.78	-0.81	0.7	0.65	-0.22	-0.23
Common Stock	0.88	0.8	0.92	-0.69	-0.94	0.96	0.47	0.98	0.75	0.85		0.41	0.55	0.32	-0.06	0.16	-0.34	0.77	-0.87	0.94	0.93	-0.54	-0.41
Property Plant Equipment	0.53	0.52	0.48	-0.44	-0.33	0.27	0.49	0.5	0.53	0.53	0.41		0.57	0.06	-0.3	-0.26	-0.37	0.31	-0.62	0.2	0.2	-0.08	-0.12
Current Deferred Revenue	0.69	0.66	0.65	-0.61	-0.51	0.46	0.49	0.67	0.47	0.69	0.55	0.57		0.06	0.13	-0.15	-0.03	0.64	-0.69	0.46	0.43	-0.22	-0.23
Net Receivables	0.33	0.33	0.39	-0.45	-0.4	0.42	-0.41	0.3	0.21	0.3	0.32	0.06	0.06		-0.02	0.14	-0.21	0.71	-0.36	0.4	0.29	-0.3	-0.26
Net Invested Capital	0.15	0.2	0.04	-0.2	0.01	-0.18	-0.1	-0.03	-0.34	0.15	-0.06	-0.3	0.13	-0.02		-0.27	0.87	0.11	0.2	0.08	0.05	0.29	0.12
Short Long Term Debt	-0.2	-0.27	0.02	0.17	-0.3	0.17	-0.55	0.01	-0.1	-0.21	0.16	-0.26	-0.15	0.14	-0.27		-0.48	-0.01	0.08	0.3	0.38	-0.85	-0.67
Net Working Capital	-0.09	-0.01	-0.2	-0.02	0.41	-0.42	-0.05	-0.29	-0.43	-0.07	-0.34	-0.37	-0.03	-0.21	0.87	-0.48		-0.18	0.45	-0.24	-0.3	0.66	0.56
Short Term Debt	0.81	0.76	0.81	-0.74	-0.81	0.8	0.21	0.82	0.55	0.78	0.77	0.31	0.64	0.71	0.11	-0.01	-0.18		-0.84	0.79	0.7	-0.41	-0.38
Intangible Assets	-0.84	-0.77	-0.82	0.62	0.86	-0.85	-0.6	-0.93	-0.73	-0.81	-0.87	-0.62	-0.69	-0.36	0.2	0.08	0.45	-0.84		-0.77	-0.75	0.42	0.4
Capital Surpluse	0.74	0.64	0.8	-0.53	-0.95	0.89	0.29	0.91	0.5	0.7	0.94	0.2	0.46	0.4	0.08	0.3	-0.24	0.79	-0.77		0.98	-0.62	-0.47
Capital Stock	0.69	0.59	0.76	-0.46	-0.96	0.86	0.3	0.88	0.47	0.65	0.93	0.2	0.43	0.29	0.05	0.38	-0.3	0.7	-0.75	0.98		-0.69	-0.56
Long Term Debt	-0.23	-0.15	-0.4	0.15	0.71	-0.54	0.22	-0.45	-0.24	-0.22	-0.54	-0.08	-0.22	-0.3	0.29	-0.85	0.66	-0.41	0.42	-0.62	-0.69		0.9
Long Term Debt Total	-0.23	-0.18	-0.31	0.15	0.66	-0.4	0.21	-0.34	-0.17	-0.23	-0.41	-0.12	-0.23	-0.26	0.12	-0.67	0.56	-0.38	0.4	-0.47	-0.56	0.9

Click cells to compare fundamentals

About Cue Biopharma Financial Statements

Cue Biopharma stakeholders use historical fundamental indicators, such as Cue Biopharma's Operating Income, to determine how well the company is positioned to perform in the future. Although Cue Biopharma investors may analyze each financial statement separately, they are all interrelated. For example, changes in Cue Biopharma's assets and liabilities are reflected in the revenues and expenses on Cue Biopharma's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Cue Biopharma. Please read more on our technical analysis and fundamental analysis pages.

	Last Reported	Projected for Next Year
Operating Income	-52.1 M	-54.8 M
Non Operating Income Net Other	57.7 K	91.8 K

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

C	Citigroup
GM	General Motors
F	Ford Motor

When determining whether Cue Biopharma is a strong investment it is important to analyze Cue Biopharma's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Cue Biopharma's future performance. For an informed investment choice regarding Cue Stock, refer to the following important reports:

How To Invest In Cue

Details

Is Cue Stock a good investment?

Details

What is Cue Biopharma's Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out the analysis of Cue Biopharma Correlation against competitors.

For information on how to trade Cue Stock refer to our How to Trade Cue Stock guide.

You can also try the Portfolio Holdings module to check your current holdings and cash postion to detemine if your portfolio needs rebalancing.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cue Biopharma. If investors know Cue will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cue Biopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(0.91)

Revenue Per Share

0.172

Quarterly Revenue Growth

0.923

Return On Assets

(0.52)

Return On Equity

(1.39)

The market value of Cue Biopharma is measured differently than its book value, which is the value of Cue that is recorded on the company's balance sheet. Investors also form their own opinion of Cue Biopharma's value that differs from its market value or its book value, called intrinsic value, which is Cue Biopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cue Biopharma's market value can be influenced by many factors that don't directly affect Cue Biopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Cue Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Cue Biopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cue Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Cue Operating Income from 2010 to 2024

Latest Cue Biopharma's Operating Income Growth Pattern

Cue Operating Income Regression Statistics

Cue Operating Income History

Other Fundumenentals of Cue Biopharma

Cue Biopharma Operating Income component correlations

About Cue Biopharma Financial Statements

Also Currently Popular

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY